E1193, an intergroup trial led by George Sledge, with survival results driving the main conclusions of the study.
FRIDAY'S GEM: overall survival in first-line metastatic breast cancer.
FRIDAY'S GEM: overall survival in first-line…
FRIDAY'S GEM: overall survival in first-line metastatic breast cancer.
E1193, an intergroup trial led by George Sledge, with survival results driving the main conclusions of the study.